We are live on ! Find out more
RAPT

RAPT Therapeutics
RAPT

Delisted

RAPT was delisted on the 2nd of March, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in RAPT Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 104 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 105 → 0 (-105)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less capital invested

Capital invested by funds: $1.02B → $0 (-$1.02B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 104

109.39% less ownership

Funds ownership: 109.39% → 0% (-109%)

Holders
–
Holders Change
-105
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
104
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MVM
Medicxi Ventures Management
Jersey
-$94.6M
2
TCM
TCG Crossover Management
California
-$87.5M
3
FIS
FCPM III Services
Netherlands
-$62.1M
4
O
OrbiMed
New York
-$55.6M
5
RI
RTW Investments
New York
-$55.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
MVM
1
Medicxi Ventures Management
Jersey
– -$94.6M -2,794,000 Closed
TCM
2
TCG Crossover Management
California
– -$87.5M -2,582,408 Closed
FIS
3
FCPM III Services
Netherlands
– -$62.1M -1,833,333 Closed
O
4
OrbiMed
New York
– -$55.6M -1,642,891 Closed
RI
5
RTW Investments
New York
– -$55.5M -1,637,165 Closed
FCMV
6
Foresite Capital Management VI
California
– -$52.9M -1,562,500 Closed
SL
7
Siren LLC
Connecticut
– -$46.6M -1,375,000 Closed
FLSM
8
Frazier Life Sciences Management
California
– -$33.3M -983,333 Closed
B
9
Braidwell
Connecticut
– -$31.5M -929,694 Closed
RG
10
Redmile Group
California
– -$30M -885,927 Closed
PA
11
Perceptive Advisors
New York
– -$28M -825,890 Closed
SCM
12
Soleus Capital Management
Connecticut
– -$25.9M -764,000 Closed
NCM
13
Nantahala Capital Management
Connecticut
– -$25.5M -754,153 Closed
IC
14
Ikarian Capital
Texas
– -$22.5M -665,271 Closed
CP
15
Caligan Partners
New York
– -$21.8M -644,400 Closed
State Street
16
State Street
Massachusetts
– -$21.7M -639,804 Closed
Citadel Advisors
17
Citadel Advisors
Florida
– -$20M -591,802 Closed
GPP
18
Great Point Partners
Connecticut
– -$19.7M -581,187 Closed
OCA
19
Octagon Capital Advisors
New York
– -$19.4M -574,000 Closed
ACM
20
ADAR1 Capital Management
Texas
– -$17.3M -509,679 Closed
BlackRock
21
BlackRock
New York
– -$16.5M -486,153 Closed
BCM
22
Boone Capital Management
Georgia
– -$15.9M -470,456 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$14.4M -424,862 Closed
MB
24
MPM BioImpact
Massachusetts
– -$13.5M -397,906 Closed
BFM
25
Boothbay Fund Management
New York
– -$13.2M -390,747 Closed
1
2 3 4 5

RAPT Hedge Fund Activity: Q1 2026 in Review

0 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2026, worth a combined $0 — down 100% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 104 funds closed out of RAPT and 0 opened new positions — a net loss of 104 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $94.6M sold.

  • 0 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2026, down from 105 in Q4 2025.
  • Funds reported $0 of RAPT Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new RAPT Therapeutics positions in Q1 2026 and 104 closed out, a net change of -104 holders.
  • The largest RAPT Therapeutics seller in Q1 2026 was Medicxi Ventures Management, an estimated $94.6M sold.

Based on aggregated 13F filings for Q1 2026.